The Senate committee weighing the nominee to head the FDA postponed a vote and asked the agency to conduct an investigation into allegations made by an anonymous agency employee against Lester Crawford, who has been serving as interim administrator. The nature of the allegations was not disclosed. Further, a pair of senators have said they plan to block Crawford's nomination until the agency acts on Barr Pharmaceutical's application to allow OTC sales of its "morning-after" contraceptive pill.

Related Summaries